Last reviewed · How we verify
NCT05649462
Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis
trial in Ulcerative Colitis in 80 participants. Completed in 1 June 2022.
1 November 2021
Quick facts
| Lead sponsor | Second Affiliated Hospital of Wenzhou Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 January 2020 |
| Primary completion | 1 November 2021 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across China |
Conditions studied
- Ulcerative Colitis — all drugs for Ulcerative Colitis →
- Vitamin D Deficiency — all drugs for Vitamin D Deficiency →
- Vitamin D Supplement — all drugs for Vitamin D Supplement →
Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Who can join
Adults 15 to 65, any sex, with Ulcerative Colitis or Vitamin D Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is uncertain whether vitD3 supplementation is beneficial for the remission of ulcerative colitis (UC). The effects of vitD3 supplements on the efficacy of vidrecizumab in Chinese UC patients were retrospectively analyzed. Methods: Patients with moderate to severe UC were recorded. These patients were initially treated with VDZ. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of VDZ and continued throughout the follow-up period. Disease activity was assessed using the modified Mayo score.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05649462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ulcerative Colitis
Currently open trials in the same condition.
- NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
- NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
- NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
- NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
- NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting
Other Second Affiliated Hospital of Wenzhou Medical University trials
Trials by the same sponsor.
- NCT07466511 — Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis · NA · not yet recruiting
- NCT07530848 — Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients · not yet recruiting
- NCT07346443 — Mechanism Study of G Protein-coupled Receptor 81 in Multiple Organ Dysfunction of Heat Stroke · not yet recruiting
- NCT07353970 — Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro- · not yet recruiting
- NCT07332793 — Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05649462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Wenzhou Medical University
- Last refreshed: 14 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05649462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing